Search results
AstraZeneca earnings beat expectations as steady drug sales boost revenues | Invezz
Invezz· 4 days agoAstraZeneca plc today, on April 25, announced its earnings report for the first quarter of FY24. Are...
AstraZeneca's £18.7m boss Soriot bounces back as pharma giant reveals 18% sales growth
Evening Standard via Yahoo Finance· 4 days agoThe top-paid boss on the FTSE 100, AstraZeneca’s Pascal Soriot, bounced back today from the row over...
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Zacks· 6 days agoFree Report) will report first-quarter 2024 results on Apr 25, before market open. Sales of AstraZeneca’s key medicines, mainly cancer drugs — Lynparza, Tagrisso and Imfinzi ...
AstraZeneca overtakes Shell as Britain’s most valuable company By Proactive Investors
Investing.com· 4 days agoAstraZeneca PLC (LON:AZN)’s solid rally following Thursday’s first-quarter earnings print has made...
AstraZeneca Gets a Boost From Sales of Its Cancer Drugs
Investopedia· 4 days agoAmerican depositary receipts (ADRs) of AstraZeneca (AZN) traded near their all-time high as the...
AstraZeneca’s Lynparza to remain dominant in PARP inhibitors market with $4 billion in sales by 2027
BioPharma-Reporter· 4 days agoWhile the PARP inhibitors market has seen increasing competition over the years, Lynparza is set to...
Ryanair’s Michael O’Leary, who is up for a $108 million bonus, doesn’t see high CEO pay as a...
Fortune via Yahoo Finance· 3 hours agoStill, executive pay is a contentious subject. On the one hand, shareholders have flagged some...
FTSE 100 Live: Index hits record; Anglo American jumps on BHP bid
Proactive Investors· 4 days agoAstraZeneca PLC (LSE:AZN)’s 5.7% climb following Thursday’s first-quarter earnings print has made...
Deutsche Bank Aktiengesellschaft Reiterates “Hold” Rating for AstraZeneca (LON:AZN)
ETF DAILY NEWS· 4 days agoAstraZeneca (LON:AZN – Get Free Report)‘s stock had its “hold” rating reaffirmed by research analysts at Deutsche Bank Aktiengesellschaft in a research report issued on Tuesday ...
Britain’s Magnificent 7: Do Rolls-Royce, AstraZeneca and Unilever make the cut? By Proactive...
Investing.com· 5 days agoBritain’s Magnificent 7: Do Rolls-Royce, AstraZeneca and Unilever make the cut?